|
Glenmark starts Phase-IIb human trials of Revamilast molecule
Economic Times NEW DELHI: Glenmark Pharmaceuticals on Wednesday said it has started Phase-IIb human trials of its 'Revamilast' molecule, which is being developed for treatment of inflammatory disorders like asthma and rheumatoid arthritis. The Phase-IIb studies of … Glenmark initiates Phase IIb human trials globally for its novel molecule … |
View full post on asthma – Google News